Drug Trial Radar · NCT07251491
Psilocybin to Treat Depression in Spinal Cord Injury
Last checked: Nov 20, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Aug 6, 2026
Primary completion
Mar 1, 2028
Study completion Mar 1, 2028
Sponsor
- Lead sponsor
- James J. Peters Veterans Affairs Medical CenterFederal agency
- Sponsor type
- Federal agency
- Collaborators
- Bronx Veterans Medical Research Foundation, Inc; Usona Institute; United States Department of Defense
- First posted
- Nov 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 22 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main goal of this study is to determine if psilocybin is safe for use in people with SCI. The study will measure how people with SCI respond to three psilocybin doses: low (5mg), medium (10mg), and high (25mg). The main question the study aims to answer is: does psilocybin increase the number and severity of adverse (bad) events reported by people with SCI? These may include pain, muscle spasms, symptoms of depression, and symptoms of low or high blood pressure. The investigators will also measure how well people with SCI tolerate the psychedelic experience, and compare responses between the low (5mg), medium (10mg), and high (25mg) doses. Participants will: * Agree to be enrolled in the study for up to 13 months. * Agree to complete the seven (7) visits that are included in the psilocybin-assisted therapy. * Agree to complete follow-up study visits, including in-person visits to the James J Peters VA Medical Center, located in the Bronx, New York and remote visits. * Agree to keep a log of how they are feeling and any change in the frequency or severity of adverse events.
Conditions
- Spinal Cord Injury
- Depression - Major Depressive Disorder
- Veteran
Interventions
Psilocybin (Usona Institute)Drug
Oral capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Treatment-Related Adverse Events as Assessed by the Adverse Events Log.Time frame: Screening through study completion, an average of 13 months.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
James J. Peters Department of Veterans Affairs Medical Center
The Bronx, New York · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.